Trends in the national early warning score are associated with subsequent mortality - A prospective three-centre observational study with 11,331 general ward patients

国家早期预警评分的变化趋势与后续死亡率相关——一项前瞻性三中心观察性研究,纳入11331名普通病房患者

阅读:1

Abstract

AIM: To investigate whether trends in the NEWS values are associated with patient mortality in general ward patients. METHODS: A one-year prospective observational study in three hospitals in Finland. All data on patients' NEWS values during the first three days of general ward admissions were collected. The linear regression model was used to investigate the association of the NEWS trajectories with subsequent mortality. We used three outcome measures: 4-7-day, 4-14-day and 4-21-day mortality rates after the 0-3 days of initial hospitalization, respectively. RESULTS: The study cohort consisted of 11,331 general ward patients. The non-survivors had higher initial NEWS score values in all outcome categories (all p < 0.001). The non-survivors had a rising trajectory in their NEWS values in all the outcome categories, whereas the survivors had a downward trajectory in their NEWS values in all outcome categories (data presented as first- and third-day's median values): an increase from 5.0 to 6.0 vs. a decrease from 1.5 to 1.0 (4-7-day non-survivors vs. survivors), an increase from 4.0 to 5.0 vs. a decrease from 1.5 to 1.0 (4-14-day non-survivors vs. survivors) and an increase from 4.0 to 5.0 vs. a decrease from 1.5 to 1.0 (4-21-day non-survivors vs. survivors). In the linear regression model, these differences in trends were statistically significant in all the outcome categories (p < 0.05). CONCLUSION: The NEWS score trajectory during the first three days of general ward admission is associated with patient outcome. Further studies are warranted to determine specific thresholds for clinically relevant changes in the NEWS trajectories.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。